DKSH expands Grünenthal partnership to launch pain drugs in eight Asia-Pacific markets

By Public Technologies
  • DKSH entered a regional partnership with Grünenthal to commercialize specialty pain medicines across up to eight Asia-Pacific markets.
  • Agreement covers launches of four products, including Qutenza, Palexia, Vimovo, across markets such as Singapore, Thailand, Vietnam.
  • DKSH will provide end-to-end commercialization support, spanning regulatory, market access, medical affairs, distribution, supply chain.
  • Deal expands a prior partnership that covered three established Grünenthal medicines in the region.
  • Partnership announced Sept. 28, 2026, targeting faster access to pain therapies, supporting Grünenthal portfolio growth in Asia-Pacific.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DKSH Holding AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2405748_en) on September 28, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk